- Full Text
- Trade Journal
Incretin and Insulin Secretion Improved in Non-Diabetic Individuals by Lactobacillus reuteri Supplementation
Full text preview
SOURCE: Simon MC, Strassburger K, Nowotny B, et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: A proof of concept. Diabetes Care 2015;38:1827-1834.
Probiotics have been studied as potential therapies for patients with cardiovascular disease, 1 digestive disorders, 2 allergies, 3 and metabolic syndrome. 4 Human and animal studies involving interventions to alter the gut microbiota, including prebiotics, probiotics, or fecal transplantation, have shown conflicting effects on blood sugar metabolism. 5,6,7 Various lactobacillus strains have been studied for their effect on parameters such as body weight and insulin sensitivity. This proof-of-concept study investigated the mechanisms by which probiotics may affect parameters associated with glucose metabolism and inflammation in healthy individuals. Lactobacillus reuteri was selected for the current study as it has been demonstrated to be both safe and have strong probiotic activity compared with other lactobacillus strains. 8
In this prospective, double-blind, randomized trial, non-diabetic individuals (11 lean people with body mass index [BMI] of 23.6 ± 1.7 kg/m 2 and 10 obese people with BMI of 35.5 ± 4.9 kg/m 2 ) were randomized to treatment with L. reuteri SD5865 at a dosage of 10 10 colony-forming units or placebo twice daily for a period of four weeks. Inclusion criteria were 40-65 years of age, non-smoking, and absence of gastrointestinal disease. Also, individuals with known chronic disease, pregnancy, cancer, or treated with antibiotics within three months prior to the study were excluded. All individuals participating in the study were required to abstain from intake of other probiotic food products during the study period with no other changes to eating habits. See Table 1 for parameters assessed.
| Table 1: Parameters Assessed Prior to the Study and at the End of 4-week Intervention |
| * Anthropometric measurements* Oral glucose tolerance tests * During which the response of glucagon-like... |